{
    "data": [
        {
            "id": "4391712",
            "type": "article",
            "attributes": {
                "publishOn": "2020-11-26T12:35:53-05:00",
                "isLockedPro": false,
                "commentCount": 92,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris: At Least 20% Upside, But Not Everyone's Cup Of Tea",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105192",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "302378",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4391712-viatris-least-20-percent-upside-not-everyones-cup-of-tea"
            }
        },
        {
            "id": "4388717",
            "type": "article",
            "attributes": {
                "publishOn": "2020-11-12T23:58:03-05:00",
                "isLockedPro": false,
                "commentCount": 51,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Short Interest Peaks At 81% Just Prior To Mylan Merger, Cover Your Position",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105793",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "300164",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4388717-short-interest-peaks-81-percent-just-prior-to-mylan-merger-cover-your-position"
            }
        },
        {
            "id": "4367385",
            "type": "article",
            "attributes": {
                "publishOn": "2020-08-11T00:19:02-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan: Treating Debt And Intangibles",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20599",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "287457",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4367385-mylan-treating-debt-and-intangibles"
            }
        },
        {
            "id": "4365211",
            "type": "article",
            "attributes": {
                "publishOn": "2020-08-06T11:15:55-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Generic Drugs And Tensions With China: The Case For Mylan",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105813",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "286413",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4365211-generic-drugs-and-tensions-china-case-for-mylan"
            }
        },
        {
            "id": "4340245",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-27T12:43:58-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan-Upjohn Merger, And Other News: The Good, Bad And Ugly Of Biopharma",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "272575",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4340245-mylan-upjohn-merger-and-news-good-bad-and-ugly-of-biopharma"
            }
        },
        {
            "id": "4333436",
            "type": "article",
            "attributes": {
                "publishOn": "2020-03-22T07:20:38-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan's COVID-19 Medicine, And Other News: The Good, Bad And Ugly Of Biopharma",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "266463",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4333436-mylans-covidminus-19-medicine-and-news-good-bad-and-ugly-of-biopharma"
            }
        },
        {
            "id": "4330705",
            "type": "article",
            "attributes": {
                "publishOn": "2020-03-09T14:18:59-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Oyster Point Pharma: This Is An Attractive Dry Eye Disease Player For 2020",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102293",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "264547",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4330705-oyster-point-pharma-this-is-attractive-dry-eye-disease-player-for-2020"
            }
        },
        {
            "id": "4321497",
            "type": "article",
            "attributes": {
                "publishOn": "2020-02-05T04:48:16-05:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan Looks Attractive Heading Into Merger With Pfizer's Upjohn",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101336",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "259992",
                            "type": "sentiment"
                        },
                        {
                            "id": "259993",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4321497-mylan-looks-attractive-heading-merger-pfizers-upjohn"
            }
        }
    ]
}